Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
暂无分享,去创建一个
[1] N. Keiding,et al. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. , 2009, Scandinavian journal of haematology.
[2] R. Liang,et al. Secondary central nervous system involvement by non‐Hodgkin's lymphoma: The risk factors , 2006, Hematological oncology.
[3] I. Flinn,et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] W. Wilson,et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. , 2005, Blood.
[5] S. Adachi,et al. Rapid Improvement of Paraplegia Caused by Epidural Involvements of Burkitt’s Lymphoma With Chemotherapy , 2004, Spine.
[6] M. Hino,et al. Successful treatment with reduced-intensity stem cell transplantation in a case of relapsed refractory central nervous system lymphoma , 2003, Annals of Hematology.
[7] K. Aldape,et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. , 2003, Blood.
[8] E. Franssen,et al. CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature , 2003, Leukemia & lymphoma.
[9] Y. Ishigatsubo,et al. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphoma , 2002, Cancer.
[10] S. Kvaløy,et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] E. Thiel,et al. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes , 2002, Neurology.
[12] L. Deangelis,et al. A better way to find tumor in the CSF? , 2002, Neurology.
[13] J. Streater,et al. Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's Lymphoma , 2002, Leukemia & lymphoma.
[14] I. Lossos,et al. Central Nervous System Relapse of Systemic Non-Hodgkin's Lymphoma: Results of Treatment Based on High-dose Methotrexate Combination Chemotherapy , 2002, Leukemia & lymphoma.
[15] T. Batchelor,et al. High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma. , 2001, Clinical lymphoma.
[16] K. Hoang-Xuan,et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Tilly,et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients , 2000 .
[18] S. Horning,et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] H Fujita,et al. Predictive Factors for Central Nervous System Involvement in Non-Hodgkin's Lymphoma: Significance of Very High Serum LDH Concentrations , 2000, Leukemia & lymphoma.
[20] S. Phuphanich,et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C Tondini,et al. Diffuse large-cell lymphoma of the testis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Twijnstra,et al. Presenting features and value of diagnostic procedures in leptomeningeal metastases , 1999, Neurology.
[23] F. Gherlinzoni,et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. , 1999, Leukemia & lymphoma.
[24] J. Shinoda,et al. Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma. , 1998, Cancer letters.
[25] L. Recht,et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Mclaughlin,et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.
[27] B. Cole,et al. Cerebrospinal fluid cytology in patients with cancer , 1998, Cancer.
[28] J. Hermans,et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. , 1997, Archives of neurology.
[29] K. van Besien,et al. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] B. Andersson,et al. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Stamatoullas,et al. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. , 1996, Bone marrow transplantation.
[32] M. Kersten,et al. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. , 1996, Blood.
[33] A. Goldstone,et al. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[35] D. Ettinger,et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] D. Weisenburger,et al. Central Nervous System Involvement in Patients with Diffuse Aggressive Non‐Hodgkin's Lymphoma , 1991, American journal of clinical oncology.
[37] K. Wallner,et al. Reversal of cranial nerve dysfunction with radiation therapy in adults with lymphoma and leukemia. , 1990, International journal of radiation oncology, biology, physics.
[38] H. Kirshner,et al. Successful chemotherapeutic treatment of epidural compression in non‐Hodgkin's lymphoma , 1982, Cancer.
[39] H. Yokoo,et al. Intraepithelial carcinoma concomitant with esophageal carcinoma , 1962, Cancer.
[40] T. Batchelor,et al. Metastatic neurologic complications of non-Hodgkin’s lymphoma , 2005, Current oncology reports.
[41] I. Schmidt-Wolf,et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. , 2004, Haematologica.
[42] T. Molina,et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] V. Levin,et al. Cancer in the nervous system , 1996 .
[44] K. Thorling,et al. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. , 1996, Acta oncologica.
[45] J. Coindre,et al. Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients. , 1987, Oncology.